Brilliant Violet 421™ anti-mouse CD69 Antibo
- 产品名称：
- Brilliant Violet 421™ anti-mouse CD69 Antibo
- 产品类别：
- 抗体
- 产品编号：
- 104527
- 产品应用：
- 104527
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Armenian Hamster
- Immunogen
- Mouse dendritic epidermal T cell line Y245
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- ?g size: 0.2 mg/mL?L size: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.
This antibody has been characterized in the literature as containing a lambda (?) light chain.
- Application References
(PubMed link indicates BioLegend citation) -
- Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
- Sobel ES, et al. 1993. J. Immunol. 150:673.
- Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
- Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
- Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
- Lawson BR, et al. 2007. J. Immunol. 178:5366.
- Lee JW, et al. 2006. Nature Immunol. 8:181.
- Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
- Jordan JM, et al. 2008. 76:3717. PubMed
- Kenna TJ, et al. 2008. Blood 111:2091. PubMed
- Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
- Product Citations
-
- Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
- Li X, et al. 2022. Nat Commun. 13:2794. PubMed
- Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
- Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed
- Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed
- Yu S, et al. 2016. Mol Ther. 10.1038/mt.2016.175. PubMed
- Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
- Kim S, et al. 2021. Elife. 10:. PubMed
- Chandana M, et al. 2022. Nat Commun. 13:4028. PubMed
- Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
- Jin C, et al. 2019. Cell. 176:998. PubMed
- Beura LK, et al. 2018. Immunity. 48:327. PubMed
- Nair S, et al. 2021. JCI Insight. 6:. PubMed
- Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
- Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
- Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
- Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
- Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
- RRID
- AB_10900250 (BioLegend Cat. No. 104527) AB_2686969 (BioLegend Cat. No. 104545) AB_2562328 (BioLegend Cat. No. 104528)
- Structure
- C-type lectin, 27/33 kD
- Distribution
-
Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets
- Function
- Lymphocyte activation
- Cell Type
- B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
- Biology Area
- Costimulatory Molecules, Immunology, Innate Immunity
- Molecular Family
- CD Molecules
- Antigen References
-
1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.
- Gene ID
- 12515 View all products for this Gene ID
- UniProt
- View information about CD69 on UniProt.org
